



Adamantane in Drug Delivery

Guest Editor:

Prof. Dr. Ruža Frkanec

Centre for Research and
Knowledge Transfer in
Biotechnology, University of
Zagreb, Rockefellerova 10, 10000
Zagreb, Croatia

Deadline for manuscript
submissions:
closed (31 October 2022)

Message from the Guest Editor

Dear Colleagues,

Nanomedicine offers a new platform for drug delivery development. Great progress has been made in the field of cancer nanomedicine, regenerative medicine, immunotherapy, gene delivery and bioimaging. The unique structural and chemical properties of adamantane provide exceptional opportunities in the design of various adamantane-based scaffolds or carrier systems for drug delivery. Adamantane can be used in two ways; as a building block to which different functional groups are covalently bonded or as part of self-assembled supramolecular systems where adamantane is accommodated on the basis of its lipophilicity and strong host-guest interaction. Due to its lipophilicity, adamantane attachment to drugs with low hydrophobicity could increase the drug uptake through the lipidic membranes. Additional important features of adamantane are its biocompatibility and non-toxicity, as well as its low cost and easy accessibility. Nanomaterials containing adamantane and other diamondoids therefore remain highly relevant to nanomedicine, especially in the design of safe and selective drug delivery systems and molecular carriers.

Prof. Dr. Ruža Frkanec
Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics,
Ernest Mario School of
Pharmacy, Rutgers University,
Piscataway, NJ 08854, USA

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Contact Us

Pharmaceutics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceutics
pharmaceutics@mdpi.com
X@MDPIpharma